Abstract: . . .  enzyme pyruvate kinase. It is strongly overexpressed in tumor cells due to their modified metabolic state. It can be quantified in EDTA plasma with a commercially available ELISA test kit. Recent reports indicate that Tumor M2-PK is a marker for renal cell carcinoma and lung cancer [1,2]. It has also been investigated in pancreatic cancer and gastric cancer with promising results [3]. This study was designed to evaluate the use of this marker in gastrointestinal cancer . Because elevation of tumor markers . . .
. . .  specificity patients cutoff 89.7% 61 / 68 15 U/ml 95.6% 65 / 68 18 U/ml Inflammatory bowel disease n=30 min: 3.0 U/ml max: 190.4 U/ml specificity patients cutoff 66.7% 20 / 30 15 U/ml 76.7% 23 / 30 18 U/ml Table 3: Sensitivity of Tumor M2-PK, CA 19-9 and CEA in gastrointestinal cancer total GI colorectal gastric&esoph. pancreatic hepatobiliary cancer cancer cancer cancer cancer Tumor M2-PK 64.8% 72.7% 47.0% 62.5% 85.7% cutoff: 15 U/ml Tumor M2-PK 55.5% 63.6% 41.1% 62.5% 71.4% cutoff: 18 U/ml CA 19-9 . . .
. . .  in this disease so far. In conclusion, Tumor M2-PK appears to be a promising marker in gastrointestinal cancer and further research with this marker should be undertaken. References: [1] Oromek GM, Teigelkamp S, Kramer W, Eigenbrodt E and Usadel KH: The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker ifor renal carcinoma. Anticancer Research 19: 2599-2602, 1999. [2] Schneider J, Morr H, Velcovsky HG, Eigenbrodt E: Quantitativer Nachweis von Tumor M2-Pyruvatkinase in EDTA-Plasma bei . . .
--1507,3,251,1721,7535